Farnesoid X receptor modulators
US-10532061-B2 · Jan 14, 2020 · US
Farnesoid X receptor modulators
US11034717B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11034717-B2 |
| Application number | US-201615288390-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 7, 2016 |
| Priority date | Oct 7, 2015 |
| Publication date | Jun 15, 2021 |
| Grant date | Jun 15, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present application provides a compound of formula I:or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1-R10, m, n, p, and are as described herein. The present invention relates generally to FXR modulators and to methods of making and using said compounds.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound selected from: or a pharmaceutically acceptable salt or solvate thereof. 2. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier or excipient. 3. The compound of claim 1 , which is or a pharmaceutically acceptable salt or solvate thereof. 4. The compound of claim 3 , which is or a pharmaceutically acceptable salt thereof. 5. The compound of claim 3 , which is 6. The compound of claim 1 , which is or a pharmaceutically acceptable salt or solvate thereof. 7. The compound of claim 6 , which is or a pharmaceutically acceptable salt thereof. 8. The compound of claim 6 , which is 9. A pharmaceutical composition comprising the compound of claim 3 or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier or excipient. 10. A pharmaceutical composition comprising the compound of claim 6 or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier or excipient.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Drugs for disorders of the nervous system · CPC title
Antineoplastic agents · CPC title
Antibacterial agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11034717B2 cover?
- The present application provides a compound of formula I:or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1-R10, m, n, p, and are as described herein. The present invention relates generally to FXR modulators and to methods of making and using said compounds.
- Who is the assignee on this patent?
- Intercept Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification C07J43/003. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).